BACKGROUND: The economic impact of therapies has increasingly become part of the clinical decision-making process. Costs associated with kidney transplantation are substantial and economic evaluations are useful in identifying immunosuppressive regimens that yield optimal clinical and economic benefits. METHODS: Utilisation of health care resources during the first 6-months after renal transplantation was examined in 557 kidney transplant recipients participating in a European, multicentre, randomised, parallel group study that compared the efficacy and safety of a tacrolimus-based regimen versus a cyclosporin-microemulsion-based regimen. Cost-minimisation and cost-effectiveness analyses were conducted from an Italian hospital perspective, including direct medical costs only (e.g. medication, hospitalisation). RESULTS: The incidence of acute rejection was significantly lower in the tacrolimus group than in the cyclosporin microemulsion (ME) group (32.5% versus 51.3%; p<0.001). Patient and graft survival were similar in both treatment groups. Renal transplant recipients receivingtacrolimus-based immunosuppression had lower utilisation of health care resources and lower total costs per patient than cyclosporin-ME treated patients. When surviving patients with a rejection-free graft were analysed, tacrolimus therapy was cost-saving, since it was both more effective (18.8% difference in the incidence of acute rejection; 95%CI 10.7%-26.8%; p<0.001) and less costly than cyclosporin-ME based therapy (cost difference euro9918). The costs per patient with a functioning graft were euro2305, the costs per surviving patient were euro1892 lower in tacrolimus treated patients. Sensitivity analyses using the key cost-drivers (hospitalisation, study drug, and concomitant medication) found the cost advantage of tacrolimus was maintained. CONCLUSION: In the first 6 months after renal transplantation, tacrolimus-based therapy was less costly than cyclosporin-ME based therapy. When surviving patients with a rejection-free graft were considered, tacrolimus was the dominant therapy.
RCT Entities:
BACKGROUND: The economic impact of therapies has increasingly become part of the clinical decision-making process. Costs associated with kidney transplantation are substantial and economic evaluations are useful in identifying immunosuppressive regimens that yield optimal clinical and economic benefits. METHODS: Utilisation of health care resources during the first 6-months after renal transplantation was examined in 557 kidney transplant recipients participating in a European, multicentre, randomised, parallel group study that compared the efficacy and safety of a tacrolimus-based regimen versus a cyclosporin-microemulsion-based regimen. Cost-minimisation and cost-effectiveness analyses were conducted from an Italian hospital perspective, including direct medical costs only (e.g. medication, hospitalisation). RESULTS: The incidence of acute rejection was significantly lower in the tacrolimus group than in the cyclosporin microemulsion (ME) group (32.5% versus 51.3%; p<0.001). Patient and graft survival were similar in both treatment groups. Renal transplant recipients receiving tacrolimus-based immunosuppression had lower utilisation of health care resources and lower total costs per patient than cyclosporin-ME treated patients. When surviving patients with a rejection-free graft were analysed, tacrolimus therapy was cost-saving, since it was both more effective (18.8% difference in the incidence of acute rejection; 95%CI 10.7%-26.8%; p<0.001) and less costly than cyclosporin-ME based therapy (cost difference euro9918). The costs per patient with a functioning graft were euro2305, the costs per surviving patient were euro1892 lower in tacrolimus treated patients. Sensitivity analyses using the key cost-drivers (hospitalisation, study drug, and concomitant medication) found the cost advantage of tacrolimus was maintained. CONCLUSION: In the first 6 months after renal transplantation, tacrolimus-based therapy was less costly than cyclosporin-ME based therapy. When surviving patients with a rejection-free graft were considered, tacrolimus was the dominant therapy.